540 related articles for article (PubMed ID: 34712689)
1. Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study.
Liu L; Sheng C; Lyu Z; Dai H; Chen K
Front Nutr; 2021; 8():755834. PubMed ID: 34712689
[TBL] [Abstract][Full Text] [Related]
2. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
3. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
[TBL] [Abstract][Full Text] [Related]
4. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
[TBL] [Abstract][Full Text] [Related]
5. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
[TBL] [Abstract][Full Text] [Related]
6. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
He JY; Zhang X; Wang K; Lv WQ
J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
[TBL] [Abstract][Full Text] [Related]
7. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study.
Soremekun O; Karhunen V; He Y; Rajasundaram S; Liu B; Gkatzionis A; Soremekun C; Udosen B; Musa H; Silva S; Kintu C; Mayanja R; Nakabuye M; Machipisa T; Mason A; Vujkovic M; Zuber V; Soliman M; Mugisha J; Nash O; Kaleebu P; Nyirenda M; Chikowore T; Nitsch D; Burgess S; Gill D; Fatumo S
EBioMedicine; 2022 Apr; 78():103953. PubMed ID: 35325778
[TBL] [Abstract][Full Text] [Related]
8. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
[TBL] [Abstract][Full Text] [Related]
9. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
Liang Z; Zhao L; Lou Y; Liu S
QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
[TBL] [Abstract][Full Text] [Related]
10. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study.
Zhao SS; Yiu ZZN; Barton A; Bowes J
JAMA Dermatol; 2023 Mar; 159(3):275-280. PubMed ID: 36696131
[TBL] [Abstract][Full Text] [Related]
11. Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and Women: A Drug-Target Mendelian Randomization Study.
Bell AS; Rosoff DB; Mavromatis LA; Jung J; Wagner J; Lohoff FW
J Am Heart Assoc; 2022 Nov; 11(21):e026122. PubMed ID: 36285785
[TBL] [Abstract][Full Text] [Related]
12. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
Qiao L; Lv S; Meng K; Yang J
Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
[TBL] [Abstract][Full Text] [Related]
13. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
[TBL] [Abstract][Full Text] [Related]
14. LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization Study.
Dib MJ; Zagkos L; Meena D; Burgess S; Chirinos JA; Gill D
Stroke; 2024 Jun; 55(6):1676-1679. PubMed ID: 38572634
[TBL] [Abstract][Full Text] [Related]
15. Association between genetically proxied lipid-lowering drug targets, lipid traits, and amyotrophic lateral sclerosis: a mendelian randomization study.
Yan Z; Xu Y; Li K; Liu L
Acta Neurol Belg; 2024 Apr; 124(2):485-494. PubMed ID: 37889424
[TBL] [Abstract][Full Text] [Related]
16. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.
Yarmolinsky J; Bouras E; Constantinescu A; Burrows K; Bull CJ; Vincent EE; Martin RM; Dimopoulou O; Lewis SJ; Moreno V; Vujkovic M; Chang KM; Voight BF; Tsao PS; Gunter MJ; Hampe J; Pellatt AJ; Pharoah PDP; Schoen RE; Gallinger S; Jenkins MA; Pai RK; ; ; Gill D; Tsilidis KK
Diabetologia; 2023 Aug; 66(8):1481-1500. PubMed ID: 37171501
[TBL] [Abstract][Full Text] [Related]
17. Association of genetic variants related to combined lipid-lowering and antihypertensive therapies with risk of cardiovascular disease: 2 × 2 factorial Mendelian randomization analyses.
Li Y; Liu H; Shen C; Li J; Liu F; Huang K; Gu D; Li Y; Lu X
BMC Med; 2024 May; 22(1):201. PubMed ID: 38764043
[TBL] [Abstract][Full Text] [Related]
18. Genetic Association of Lipid-Lowering Drugs with Aortic Aneurysms: A Mendelian Randomization Study.
Gao X; Luo W; Qu L; Yang M; Chen S; Lei L; Yan S; Liang H; Zhang X; Xiao M; Liao Y; Lee AP; Zhou Z; Chen J; Zhang Q; Wang Y; Xiu J
Eur J Prev Cardiol; 2024 Feb; ():. PubMed ID: 38302118
[TBL] [Abstract][Full Text] [Related]
19. Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis.
Chen H; Zhou X; Hu J; Li S; Wang Z; Zhu T; Cheng H; Zhang G
Lipids Health Dis; 2023 Dec; 22(1):220. PubMed ID: 38082436
[TBL] [Abstract][Full Text] [Related]
20. Association between genetically proxied PCSK9 inhibition and systemic lupus erythematosus risk: A mendelian randomization study.
Ji X; Guo HY; Han M; Peng H; Yuan H
Int J Rheum Dis; 2024 Apr; 27(4):e15106. PubMed ID: 38568054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]